Eton Pharmaceuticals (ETON)
(Delayed Data from NSDQ)
$14.73 USD
+0.34 (2.36%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $14.72 -0.01 (-0.07%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ETON 14.73 +0.34(2.36%)
Will ETON be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ETON based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ETON
Eton Pharmaceuticals, Inc. (ETON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Eton Pharmaceuticals (ETON) Upgraded to Buy: Here's Why
ETON: What are Zacks experts saying now?
Zacks Private Portfolio Services
Eton Pharmaceuticals (ETON) Is a Great Choice for 'Trend' Investors, Here's Why
Eton Pharmaceuticals, Inc. (ETON) Q1 Earnings Lag Estimates
TELA Bio, Inc. (TELA) Reports Q1 Loss, Tops Revenue Estimates
Other News for ETON
Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, ...
BlackRock, Inc. Expands Stake in Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc (ETON) Shares Up 8.03% on Jul 18
Eton Pharma Near Term Catalysts Vanish
Eton Pharmaceuticals management to meet with B. Riley